Trials / Completed
CompletedNCT06776679
A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-BGB-16673 Following a Single Oral Dose in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the absorption, metabolism, and excretion of \[14C\]-BGB-16673 and to characterize and determine, where possible, the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-BGB-16673 | Administered orally as suspension in lipid vehicle |
Timeline
- Start date
- 2025-01-24
- Primary completion
- 2025-03-27
- Completion
- 2025-03-27
- First posted
- 2025-01-15
- Last updated
- 2025-05-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06776679. Inclusion in this directory is not an endorsement.